Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kiniksa Pharmaceuticals International (KNSA) Accounts Payables (2021 - 2025)

Historic Accounts Payables for Kiniksa Pharmaceuticals International (KNSA) over the last 5 years, with Q3 2025 value amounting to $6.1 million.

  • Kiniksa Pharmaceuticals International's Accounts Payables fell 2615.27% to $6.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $6.1 million, marking a year-over-year decrease of 2615.27%. This contributed to the annual value of $2.0 million for FY2024, which is 7527.29% down from last year.
  • Latest data reveals that Kiniksa Pharmaceuticals International reported Accounts Payables of $6.1 million as of Q3 2025, which was down 2615.27% from $9.0 million recorded in Q2 2025.
  • Over the past 5 years, Kiniksa Pharmaceuticals International's Accounts Payables peaked at $9.0 million during Q2 2025, and registered a low of $648000.0 during Q2 2023.
  • Moreover, its 5-year median value for Accounts Payables was $2.8 million (2021), whereas its average is $4.1 million.
  • Over the last 5 years, Kiniksa Pharmaceuticals International's Accounts Payables had its largest YoY gain of 104089.51% in 2024, and its largest YoY loss of 7527.29% in 2024.
  • Kiniksa Pharmaceuticals International's Accounts Payables (Quarter) stood at $1.9 million in 2021, then surged by 322.86% to $7.9 million in 2022, then increased by 4.39% to $8.2 million in 2023, then crashed by 75.27% to $2.0 million in 2024, then surged by 201.62% to $6.1 million in 2025.
  • Its Accounts Payables stands at $6.1 million for Q3 2025, versus $9.0 million for Q2 2025 and $2.0 million for Q1 2025.